AstraZeneca announces FDA approval of Voydeya

Voydeya has been approved in the U.S. as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysism or EVH, in adults with paroxysmal nocturnal hemoglobinuria. Voydeya is an oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris or Soliris to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.